Investor Roadmap

Full name of the company

“Minskintercaps” Production Republican Unitary Enterprise

Primary activity

Manufacture of pharmaceuticals

Products, services description (detailed, indicating CN FEA code)

“Minskintercaps” Production Republican Unitary Enterprise is a pharmaceutical entity engaged in drug manufacturing of drugs in Soft and Hard Gelatin capsules of various PT(pharmacotherapeutic) groups (HSN code List 3004)

Superior body

The Pharmaceutical Holdings Company "Belpharmprom"

General reference and analytical information about the company

The enterprise registered 69 drugs in the domestic market. 208 Registration Certificates are in States of near and far abroad. 81 APIs were registered. Drug manufacture of realized by “Minskintercaps” U.V. has been certified in full for the compliance with the requirements of Good Manufacturing Practice (GMP), TCP 030-2017, for ISO 14000, ISO 45000, and for the compliance with Regulations of the European Parliament and of the Council (EC) “On Food Hygiene”, Codex Alimentarius (or Food Code) – general guidelines of food hygiene. The enterprise has its full-time staff, up-to-date process equipment, advanced infrastructure, and adequate driveway.

Authorized capital size of the company, thousand $

0.15

Distribution of shares (by owners)

100% state ownership

Revenue, thousand $

7044

Net profit (net loss), thousand $

847

Current liquidity ratio

9.85

Working capital financed by equity to total assets ratio

0.898

Assets ratio of financial liabilities

0.3

Number of employees as on the month of filling the form, people

364

Average salary as on the month of filling the form, BYN

1772,1

Type of investment project

Project in progress

Total volume of investments, thousand $

8174.2

Expected input of an investor, thousand $

5126.7

Project period

2021-2025

Investor participation form

credit financing

Project description

Pre-requisites: Expiration of the Certificate validity granted for the old production building. Goals: Construction and assembly operations in another building with further arrangement of new utilities and purchasing equipment lines. Participation in financing. Concern: To allocate the Investor’s technologies on the new production site.

The nomenclature of the product to be produced with indication of the CN FEA code

Drugs in Soft Gelatin Capsules (HSN code List 3004).

Volume of investments, thousand $

8174.2

Annual revenues once fully operational (without VAT, thousand $)

33109.1

Dymanic pay-back period, yrs

6.06

NPV, thousand $

1 895,9

IRR, %

16.93

Discount Rate, %

9.79

Potential customer

Enterprises of RUP “PHARMACY”, wholesale companies and pharmacy chains of private ownership. Foreign distributors and pharmacy chains, including States of EAEU, Middle East and Asia. Domestic market: market share in 2021 was 2.32%, by 2026 NLT 3%.

Key benefits of the project

1) Possible production of various serial products 2) Import substitution 3) Vacant manufacturing facilities 4) Competitive features of Soft Gelatin Capsules 5) Access to EAEU market

Level of project development: feasibility study, business-plan (indicating the date of development), pre-investment study, design estimate documentation, construction work in progress etc.

Developed project documentation; carried out expert examination (Statement dd.23/11/2021 N.533-17/21) and project qualificationи. Available draft business-plan (Date: 01/11/2021.)

Volume of imports to the Republic of Belarus, thousand $

9 500

Volume of exports from the Republic of Belarus, thousand $

10 264

Simple pay-back period, yrs

5.33

The effect of the investment project

import substitution

Download document 1